In this interview, Shirish M. Gadgeel, MD, MBBS, medical oncologist at Michigan Medicine, University of Michigan, provides insights into multikinase tyrosine kinase inhibitor (TKI) treatments and their varied observed efficacy in patients with different tumor types. In particular, he observes that multikinase TKIs appear to be more efficacious in medullary thyroid carcinoma with RET alterations than they are when targeting non-small cell lung cancer with RET alterations.

Read the full interview transcript by clicking here.